List of Excipients in Branded Drug TYRVAYA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Oyster Point Pharma Inc	TYRVAYA	varenicline	73521-030	HYDROCHLORIC ACID
Oyster Point Pharma Inc	TYRVAYA	varenicline	73521-030	SODIUM CHLORIDE
Oyster Point Pharma Inc	TYRVAYA	varenicline	73521-030	SODIUM HYDROXIDE
Oyster Point Pharma Inc	TYRVAYA	varenicline	73521-030	SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

Tyrvaya Excipient Strategy and Commercial Opportunities in Dry Eye Disease

Last updated: August 6, 2026

Tyrvaya is a preservative-free, aqueous nasal spray containing varenicline tartrate for temporary increases in tear production in patients with dry eye disease. Its commercial differentiation comes from delivery route, not from a novel active ingredient. The excipient system supports nasal tolerability, isotonicity, pH control, chemical stability, and repeated use from a multidose device. The main commercial opportunities are expansion of the dry-eye treatment population, combination use with topical ophthalmic products, device and formulation lifecycle management, and geographic licensing.

What is Tyrvaya and how does its formulation work?

Tyrvaya contains varenicline tartrate, equivalent to 0.03 mg of varenicline per 0.1 mL spray. The approved dose is one spray in each nostril twice daily. The product is administered intranasally and is intended to activate the trigeminal parasympathetic pathway associated with tear production rather than deliver varenicline directly to the ocular surface (U.S. Food and Drug Administration [FDA], 2021).

Tyrvaya formulation profile

Attribute	Tyrvaya specification
Active ingredient	Varenicline tartrate
Strength	0.03 mg varenicline per spray
Dosage form	Nasal spray
Route	Intranasal
Dose frequency	One spray per nostril twice daily
Indication	Temporary increase in tear production in adults with dry eye disease
Preservative status	No preservative is identified in the FDA inactive-ingredient list
Primary excipients	Sodium phosphate dibasic anhydrous, sodium phosphate monobasic monohydrate, sodium chloride, water for injection
FDA approval	October 15, 2021
NDA	214465
Original sponsor	Oyster Point Pharma
Current commercial owner	Viatris, following its acquisition of Oyster Point Pharma

The formulation uses a conventional phosphate-buffered saline platform. Its commercial value comes from how that platform is combined with low-dose varenicline and a nasal metered-dose device.

What excipients are used in Tyrvaya?

Tyrvaya uses four principal inactive ingredients identified in the FDA prescribing information:

1. Sodium phosphate dibasic anhydrous.
2. Sodium phosphate monobasic monohydrate.
3. Sodium chloride.
4. Water for injection.

The excipients are functional rather than pharmacologically active.

How does each excipient support the product?

Excipient	Primary formulation role	Commercial and technical relevance
Sodium phosphate dibasic anhydrous	Buffer component and pH control	Helps maintain chemical stability and nasal tolerability
Sodium phosphate monobasic monohydrate	Buffer component	Works with dibasic phosphate to establish the target pH
Sodium chloride	Tonicity adjustment	Reduces the risk of discomfort from a hypotonic or hypertonic nasal solution
Water for injection	Vehicle	Provides the aqueous continuous phase for the spray

The formulation does not rely on a conventional antimicrobial preservative. That design is commercially relevant because chronic dry-eye patients may already use multiple preserved ophthalmic products. Removing benzalkonium chloride and similar preservatives can support a tolerability-based marketing position, although nasal administration introduces its own local tolerability considerations.

Why is a preservative-free nasal formulation commercially important?

Preservative-free delivery is a meaningful product attribute in chronic-use dry-eye therapy. Many patients use artificial tears, prescription anti-inflammatory drops, gels, or ointments over extended periods. A preservative-free product can be positioned for patients who experience ocular-surface sensitivity or who want to reduce cumulative preservative exposure.

Tyrvaya also avoids direct instillation onto the ocular surface. That creates several commercial advantages:

• It does not require corneal contact during administration.
• It can be used without placing a drop directly on an irritated eye.
• It targets a neural pathway associated with natural tear production.
• It offers a non-ocular delivery option for patients who have difficulty instilling eye drops.
• It may fit treatment regimens that already contain topical anti-inflammatory or immunomodulatory products.

The value proposition is therefore based on route of administration and mechanism, supported by a simple excipient system.

What formulation and device barriers protect Tyrvaya?

The active ingredient, varenicline, is not new to medicine. Oral varenicline was previously marketed as Chantix for smoking cessation. Tyrvaya’s protection therefore depends primarily on the nasal dosage form, formulation, device, manufacturing process, and method of use rather than on basic composition-of-matter rights covering varenicline.

Potential protection categories

Protection category	Relevance to Tyrvaya
Nasal formulation	May cover concentration, pH, buffer composition, tonicity, and chemical stability
Method of use	May cover intranasal administration of varenicline to increase tear production
Device	May cover metered spray delivery, dose uniformity, plume characteristics, and container closure
Manufacturing process	May cover mixing, filling, sterilization or bioburden control, and device assembly
Packaging	May protect unit configuration, bottle design, actuator, and dosing presentation
Clinical-use claims	May cover patient populations, dosing frequency, or use with other dry-eye therapies

The most important barrier for a generic entrant is likely to be a combination of formulation equivalence, nasal-device performance, and regulatory demonstration of pharmaceutical equivalence. A simple varenicline solution is unlikely to reproduce all product attributes without development work on pH, osmolality, spray performance, droplet-size distribution, plume geometry, extractables, leachables, and container compatibility.

When does Tyrvaya lose regulatory exclusivity?

Tyrvaya did not receive new chemical entity exclusivity because varenicline had already been approved in an oral product. Its approval was based on a new route, dosage form, and clinical development program.

The product received three-year exclusivity associated with new clinical investigations supporting the nasal formulation and indication. That period began with FDA approval on October 15, 2021 and generally expired in October 2024, subject to the exact FDA exclusivity listing and any applicable regulatory adjustments (FDA, 2021).

Regulatory exclusivity and patent protection are separate. The expiration of three-year exclusivity does not eliminate formulation, method-of-use, device, or manufacturing patents.

What is the Orange Book status of Tyrvaya?

Tyrvaya is an FDA-approved prescription drug marketed under NDA 214465. Orange Book protection for the product is expected to center on patents covering the nasal formulation, use of varenicline for dry-eye disease, and potentially the delivery system.

For commercial planning, the key distinction is between:

• Listed patents that can support a Paragraph IV challenge.
• Unlisted device or manufacturing patents that may still create litigation risk.
• Method-of-use patents that may be vulnerable to a Section viii carve-out.
• Formulation patents that can block an otherwise equivalent generic product.
• Patents that expire before the practical launch date because of litigation or regulatory delay.

A generic applicant could pursue an ANDA with a Paragraph IV certification against listed patents. A method-of-use patent may be avoidable if the generic labeling excludes the patented indication, but that strategy depends on the scope of the claims and FDA labeling requirements.

Which companies are challenging Tyrvaya?

No major public generic challenge is established in the core regulatory sources cited here. The likely competitive pressure comes from generic-drug companies with nasal-spray development capabilities, ophthalmic manufacturers, and companies seeking to repurpose varenicline or related cholinergic agonists for ocular-surface disease.

A serious challenger would need to solve four problems:

1. Demonstrate pharmaceutical equivalence to the approved nasal spray.
2. Match or justify differences in spray performance.
3. Address formulation and device patents.
4. Avoid an indication-limited launch that reduces commercial value.

The most credible challengers would be companies with experience in nasal suspensions, multidose preservative-free systems, and complex combination-device products.

How strong is the Tyrvaya patent estate?

The estate is structurally stronger than a conventional repurposed-drug estate because it can combine route-of-administration claims with use, formulation, device, and manufacturing claims. Its weakness is that the active ingredient is old and widely known.

Strength factors

• Varenicline is delivered through a differentiated route.
• The indication uses a defined biological mechanism.
• The product requires a metered nasal device.
• Formulation performance is linked to nasal tolerability and dosing consistency.
• Generic substitution may require more than simple active-ingredient matching.

Weakness factors

• Varenicline composition-of-matter protection is unavailable as a primary barrier.
• Prior-art searches can identify nasal delivery and cholinergic-agonist disclosures.
• Method-of-use claims may be vulnerable to label carve-outs.
• A basic aqueous phosphate-buffered formulation may face obviousness challenges if claim scope is narrow.
• Three-year regulatory exclusivity has ended.

Overall, the commercial patent position is likely moderate rather than composition-of-matter strong. The practical durability of the franchise depends on claim breadth, patent expiration dates, Orange Book listings, and the difficulty of reproducing the spray-device performance.

What commercial opportunities exist for Tyrvaya excipients?

The excipient strategy creates several business opportunities beyond the branded product.

Preservative-free nasal platforms

The formulation can support development of other chronic-use nasal products without benzalkonium chloride or related preservatives. Potential targets include peptides, small molecules, anti-inflammatory agents, and autonomic agonists.

Combination dry-eye therapy

Tyrvaya may be used alongside topical cyclosporine, lifitegrast, corticosteroids, artificial tears, or ocular lubricants. A combination regimen does not require physical co-formulation. The commercial opportunity lies in complementary mechanisms:

• Tyrvaya increases tear production.
• Anti-inflammatory therapies address ocular-surface inflammation.
• Lubricants provide immediate symptomatic relief.

Device licensing

The metered nasal-spray system may have value as a platform for other low-dose products. Relevant licensing targets include companies developing preservative-free intranasal products, rescue therapies, and chronic treatments requiring reliable low-volume delivery.

International expansion

Varenicline nasal spray has potential in markets where dry-eye disease is associated with aging, screen exposure, contact-lens use, autoimmune disease, or environmental stress. Expansion requires local approval, device registration, manufacturing scale-up, and reimbursement access. The product’s excipient system is relatively familiar to regulators, which may simplify CMC development compared with more complex suspensions or biologic nasal products.

Contract manufacturing

Manufacturers with sterile or low-bioburden aqueous filling, nasal-device assembly, and preservative-free packaging capabilities could supply regional launches or authorized generics. The manufacturing opportunity is more specialized than ordinary oral solid-dose production because dose uniformity and actuator performance must remain within specification throughout shelf life.

How does Tyrvaya compare with Restasis, Xiidra, and Miebo?

Product	Active ingredient	Route	Primary product distinction
Tyrvaya	Varenicline tartrate	Nasal spray	Increases tear production through nasal trigeminal pathway
Restasis	Cyclosporine	Ophthalmic emulsion	Reduces ocular-surface inflammation and improves tear production over time
Xiidra	Lifitegrast	Ophthalmic solution	Targets T-cell-mediated inflammation
Miebo	Perfluorohexyloctane	Ophthalmic solution	Reduces tear evaporation from the ocular surface

Tyrvaya occupies a different formulation and administration category. It does not compete solely on preservative status. Its main distinction is avoiding direct ocular delivery while addressing tear production. That supports combination use rather than simple one-for-one substitution.

What generic launch scenarios exist for Tyrvaya?

Scenario 1: Delayed generic entry

A generic applicant challenges patents but launches only after litigation or settlement. This preserves meaningful branded pricing while reducing long-term exclusivity.

Scenario 2: Label-carve-out entry

A generic launches with a label excluding a patented method of use. This scenario could produce limited substitution if the remaining FDA-approved uses do not capture the full commercial market.

Scenario 3: At-risk launch

A challenger launches before patent litigation is resolved. This creates substantial damages exposure if the branded sponsor proves infringement and patent validity.

Scenario 4: Authorized generic

The sponsor or licensee supplies a therapeutically equivalent product under a separate label or distributor arrangement. This can capture price-sensitive demand while moderating third-party generic penetration.

Key Takeaways

• Tyrvaya uses a simple phosphate-buffered, isotonic, preservative-free aqueous formulation.
• The excipients support pH control, tonicity, stability, and nasal tolerability.
• Commercial differentiation comes from intranasal delivery and tear-production biology, not novel varenicline chemistry.
• The primary intellectual-property value lies in formulation, method-of-use, device, and manufacturing claims.
• Three-year regulatory exclusivity likely ended in October 2024.
• Generic risk depends on Orange Book-listed patents, label-carve-out feasibility, device equivalence, and spray-performance requirements.
• The strongest commercial opportunities are combination dry-eye therapy, preservative-free nasal platforms, device licensing, international expansion, and specialized contract manufacturing.
• Tyrvaya has a moderate formulation and device patent profile but lacks composition-of-matter protection for varenicline.

FAQs

Can Tyrvaya’s excipients be used in another varenicline nasal spray?

Yes. The excipients themselves are widely used pharmaceutical materials and generally cannot support broad exclusivity alone. Protection may arise from the claimed combination, concentration ranges, pH, stability profile, device, or method of use.

Is Tyrvaya a preservative-free product?

The FDA prescribing information identifies phosphate buffers, sodium chloride, and water for injection as inactive ingredients and does not identify a conventional antimicrobial preservative.

Could a generic Tyrvaya use different excipients?

Potentially. An ANDA applicant would need to demonstrate pharmaceutical equivalence and satisfy applicable FDA requirements for product performance, stability, impurities, device operation, and bioequivalence or other applicable equivalence standards.

Does Tyrvaya compete directly with ophthalmic cyclosporine?

It competes for dry-eye prescriptions but has a different route and mechanism. In practice, it may be used as an alternative or in combination with ophthalmic anti-inflammatory therapy.

What is the most valuable lifecycle-extension strategy for Tyrvaya?

The strongest options are improved nasal devices, lower-frequency dosing, combination regimens, new dry-eye subpopulations, and international commercialization. A reformulation must provide a measurable clinical or usability advantage because the current excipient system is already relatively simple.

References

1. U.S. Food and Drug Administration. (2021). Tyrvaya (varenicline solution) nasal spray: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2021, October 15). FDA approves first nasal spray to treat signs and symptoms of dry eye disease. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. Viatris Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Viatris.

5. Oyster Point Pharma, Inc. (2021). Tyrvaya clinical and product information. Oyster Point Pharma.